Externe code Titel Onderzoeker
|
|
- Corey Briggs
- 8 years ago
- Views:
Transcription
1 Studies open voor inclusie Afdeling Medische Oncologie Fase I onderzoek en farmacokinetiek studies MOGE13 - M14AFS MOGYN10 - ISA-HPV MOHN03 - cbyl719, Cetuximab MOMEL03 - LEE011xMEK162 MOMULT05 - SYD MOMULT06 - DIET MOMULT10 - HER MOSAR09 - ABILITY MOGE15 - CL MOURO06 - LDcyclo Everolimus Phase I/II study with the combination of afatinib and selumetinib in advanced KRAS mutant positive and PIK3CA wildtype colorectal, non-small cell lung and pancreatic cancer A multicenter, open label phase I/II study to determine the safety and immune modulating effects of the therapeutic Human Papilloma Virus type 16 (HPV16) E5/E7 synthetic long peptides vaccine (ISA101) at different doses with or without interferon alpha as combination therapy with carboplatin and paclitaxel in women with HPV16 positive advanced or recurrent cervical cancer who have no curative treatment options A phase Ib dose escalation/randomized phase II, multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. A phase Ib/II, multicenter,open label, study of LEE011 in combination with MEK162 in adult patients with NRAS mutant melanoma A two part first-in-human phase I study (with expanded cohorts) with the antibody-drug-conjugate SYD985 to evaluate the safety, pharmacokinetics and efficacy in patients with locally advanced or metastatic solid tumors Improving the tolerability of the oral targeted anticancer drug pazopanib by food intake A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetcis and pharmacodynamics of anti-her3 monoclonal antibody GSK in subjects with advanced HER-3 positive solid tumors Influence of an acidic beverage (Coca-Cola) on the exposure to Imatinib (Glivec) after major gastrectomy in patients with gastrointestinal stroma tumors An open-label phase Ib study to evaluate the safety and efficacy of CCX872-B in patients with pancreatic adenocarcinoma Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer Ottevanger, P.B. Erp, van P.H. Graaf, van der W.T.A. Oktober
2 Gastro-enterologische tumoren MOGE01 - ORCHESTRA MOGE03 - EORTC40091 / BOS2 MOGE04 - RAPIDO MOGE05 - ART DECO MOGE06 - IMPACT CRC Colon A randomized multicenter clinical trial for patients with multi-organ, colorectal cancer metastases comparing the combination of chemotherapy and maximal tumor debulking versus chemotherapy alone Randomized phase II trial evaluating the efficacy of FOLFOX alone, FOLFOX plus bevacizumab and FOLFOX plus panitumumab as perioperative treatment in patients with resectable liver metastases from wild type KRAS colorectal cancer Randomized multicentre phase III study of short course radiation therapy followed by prolonged pre-operative chemotherapy and surgery in primary high risk rectal cancer compared to standard chemotherapy and surgery and optional adjuvant chemotherapy A randomized trial of dose escalation in definitive chemoradiotherapy for patients with oesophageal cancer. Image guided treatment optimalization with cetuximab for patients with metastatic colorectal cancer MOGE07 - JANUS2 MOGE09 - CAIRO4 MOGE10 - SILENT MOGE11 - CRITICS MOGE16 - PREOPANC MOGE19 - PELICAN A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study) The role of surgery of the primary tumour with few or absent symtoms in patients with synchronous unresectable metastases of colon cancer Accelerated growth of synchronous colorectal liver metastases: effects of neoadjuvant therapy A multicentre randomised phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: a multicentre randomized phase III clinical trial Pancreatic Locally advanced Irresectable Cancer Ablation in the Netherlands Graaf, van der W.T.A. Stommel, M. MOGE20 - COLOPEC MOGE21 - CHARISMA Adjuvant hyperthermic intraperitoneal chemotherapy in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial Neo-adjuvant chemotherapy followed by surgery versus surgery alone in highrisk patients with resectable colorectal liver metastases Bremers, A.J.A. Oktober
3 Gynaecologische tumoren MOGYN09 - INOVATYON MOGYN13 - OVHIPEC Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-13 months of last platinum Phase III randomised clinical trial for stage III ovarian carcinoma randomising between secondary debulking surgery with or without hyperhermic intraperitoneal chemotherapy Ottevanger, P.B. Ottevanger, P.B. Hoofd-hals tumoren MOHN06 - EORTC EnTF MOHN07 - PRONE MOHN08- MK A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as secondline therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy. Prediction of ototoxicity and nephrotoxicity in patients with locally advanced head and neck cancer treated with cisplatin-containing chemoradiotherapy A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer Netea-Maier, R.T. Mamma tumoren MOMAM01 - COBRA Change of body composition in breast cancer: all-in assessment MOMAM02 - PREVENT MOMAM08 - BOOG stop&go MOMAM10 - IMPACT MBC - Breast Prediction of everolimus-induced interstitial lung disease in breast cancer patients; maximizing efficacy by reducing toxicity An open randomized phase III study to compare 8 continuous cycles of chemotherapy with 8 cycles of intermittent (2 times 4 cycles) chemotherapy in first line treatment, in combination with bevacizumab, and second line treatment of patients with HER2/neu negative, incurable, metastatic or unresectable locally advanced breast cancer Towards patient tailored cancer treatment supported by molecular imaging IMPACT: imaging patients for cancer drug selection - metastatic breast cancer C.M.L MOMAM11 - INPRES Influence of exceptional patient characteristics on everolimus exposure Oktober
4 MOMAM12 - AFTER MOMAM15- SPOT A randomized, prospective trial of 3 weeks pre-operative hormonal treatment for hormone receptor positive breast cancer Dried blood SPOT analysis of everolimus in cancer patients (SPOT-study) Dermatologische tumoren (melanoom) MOMEL06 - COLUMBUS MOMEL16 - REPOSIT MOMEL23 - DC Melanoma A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma A phase II, open-label multicenter study of vemurafenib plus cobimetinib (GDC- 0973) in unresectable stage IIIc or metastatic melanoma Myeloid and plasmacytoid blood dendritic cells for immunotherpay of stage III melanoma patients scheduled for radical lymph node dissection Koornstra, R.H.T. Koornstra, R.H.T. Neuro-oncologische tumoren MONEU04 - EORTC26053 / CATNON Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non- 1p/19q deleted anaplastic glioma. The CATNON intergroup trial. Gijtenbeek, J.M.M. Miscellaneous MOMIS01 - PROSKIN MOMIS02 - Biopsy protocol Prospective, observational practice survey of applied skin care and management of cetuximab related skin reactions Development of a platform for next-generation DNA sequencing based personalized treatment for cancer patients: Protocol to obtain biopsies from patients with locally advanced (incurable) or metastatic cancer (CPCT - 02 biopsy protocol) Oktober
5 Urologische tumoren MOURO02 - SURE MOURO04 - VIABLE MOURO05 - ERA 223 BAY MOURO07 - IMPACT mrcc - Nier Phase II study of sunitinib rechallenge in patients with metastatic renal cell carcinoma A randomized, double blind, multicenter, parallel-group, phase III study to evaluate efficacy and safety of DCVAC/Pca versus placebo in men with metastatic castration resistant prostate cancer eligible for 1st line chemotherapy A phase III randomized, double-blind, placebo controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naive subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC). Watchful waiting in patients with good and intermediate risk metastatic clear cell renal cell carcinoma (mccrcc); an imaging guided observational approach Mulder, S.F. MOURO11 - MK MOURO15- vaccinatie mcrpc A Phase III Randomized Clinical Trial of MK-3475 versus Paclitaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer A randomized phase lla study: natural dendritic cells for immunotherapy of chemo-naive metastatic castration-resistant prostate cancer patients MOURO - BNITprostvac 301 (via Urologie) A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer MOURO - OPTIMUM (via Urologie) MOURO - ILUMINATE (via Urologie) Optimizing abiraterone (Zytiga ) therapy by exploring the relation between an early biomarker - drug exposure - as a predictor for drug response in patients with mcrpc (OPTIMUM study) Personalizing enzalutamide (Xtandi ) therapy by understanding the relation between the decrease in the expression profile of a panel of preselected microrna's, tumor related mrna's and treatment response in chemotherapy naive patients with mcrpc (ILUMINATE) Oktober
6 Bot en weke delen tumoren MOSAR01 - CREATE MOSAR03 - PREDICT Cross-tumoral phase II clinical trial exploring crizotinib (PF ) in patients with advanced tumors induced by casual alterations of ALK and/or MET Individualizing pazopanib therapy by exploring the role of early metabolic response and drug exposure as a predictor for treatment outcome in patients with STS. Graaf, van der W.T.A. Oktober
Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015
Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Advanced Refractory Solid Tumors or Lymphomas ECOG-ACRIN EAY131 (NCI CIRB) Targeted Therapy Directed by Genetic Testing in Treating
More informationTreating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
More informationMOH Policy for dispensing NEOPLASTIC DISEASES DRUGS
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted
More informationMédecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN
Médecine de précision médecine personnalisée en Oncologie Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Successful targeted drug development Rapid identification
More informationNational Cancer Drugs Fund List (Updated 13 February 2014)
National Cancer Drugs Fund List (Updated 13 February 2014) DRUG Abiraterone Aflibercept Axitinib Bendamustine NCDF APPROVED CRITERIA The treatment of metastatic castration resistant prostate cancer where
More informationProstate Cancer Studies
Prostate Cancer Studies STUDIES CURRENTLY RECRUITING MDV3100-14 A multinational, Phase 3, Randomized, Double- Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastic
More informationCetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient
Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)
More informationAnti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationBreast Clinical Trials ADJUVANT, HER2+ BRE- 186 (Cohort A & B closed) Phase II Therapeutic Eribulin provided
FOR MORE ABOUT OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS, PLEASE CONTACT THE OHC RESEARCH DEPARTMENT AT 1.800.710.4678. Breast Clinical Trials ADJUVANT, HER2+ BRE- 186 (Cohort A & B closed) Eribulin
More informationClinical Trials Currently Open At Genesis Health System
A Multicenter, Randonmized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SUN13837 Injection in Adult Subjects with Acute Spinal Cord Injury.
More informationPOLICY A. INDICATIONS
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationCome è cambiata la storia naturale della malattia
Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal
More informationtargeted therapy a guide for the patient
targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting
More informationIssues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)
Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting September 14, 2011 1 Review Team Paul G. Kluetz,
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationWhat is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
More informationCancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationUnderstanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient
Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that
More informationGynäkologische Onkologie-Klinische Studien
Gynäkologische Onkologie-Klinische Studien Breast cancer A randomized, phase 2 trial of AEZS-108 in chemotherapy refractory triple negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationGENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
More information2014-06-10 Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy 2014-05-
Sub. Sub. Status -06-16 Approved Lenalidomide - 2nd line treatment of multiple myeloma in patients who have contraindications to the use of bortezomib -06-16 Approved Lenalidomide - 2nd line treatment
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationPrimary Care Management of Colorectal Cancer
Primary Care Management of Colorectal Cancer Dr. Dan Renouf, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Primary Care Management of Colorectal Cancer Survivors Daniel
More informationProstate Cancer Treatment: What s Best for You?
Prostate Cancer Treatment: What s Best for You? Prostate Cancer: Radiation Therapy Approaches I. Choices There is really a variety of options in prostate cancer management overall and in radiation therapy.
More informationHigh Grade Gliomas: Update in Treatment and Care Ryan T. Merrell, M.D. Clinical Assistant Professor of Neurology NorthShore University HealthSystem
High Grade Gliomas: Update in Treatment and Care Ryan T. Merrell, M.D. Clinical Assistant Professor of Neurology NorthShore University HealthSystem rmerrell@northshore.org Objectives Provide updates on
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationFuture Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationBreast Cancer Treatment Guidelines
Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision
More informationBefore, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
More informationEvaluation of Treatment Pathways in Oncology: An Example in mcrpc
Evaluation of Treatment Pathways in Oncology: An Example in mcrpc Sonja Sorensen, MPH United BioSource Corporation Bethesda, MD 1 Objectives Illustrate selection of modeling approach for evaluating pathways
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationLOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT
LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of
More informationMOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
More informationStudy EudraCT Nr. Phase Function Period
1 Investigators Study Experience Name: Function: Site: Dr. Mathias Hoiczyk Investigator Universitätsklinikum Essen Westdeutsches Tumorzentrum Innere Klinik (Tumorforschung) Hufelandstr. 55 45122 Essen
More informationGastric Cancer. Brochure More information from http://www.researchandmarkets.com/reports/2228929/
Brochure More information from http://www.researchandmarkets.com/reports/2228929/ Gastric Cancer Description: Gastric cancer (GC) is one of the most common malignancies in terms of incidence and the second
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationNieuwe ontwikkelingen op het gebied van de angiogeneseremmers
Nieuwe ontwikkelingen op het gebied van de angiogeneseremmers Emile Voest, MD, PhD Department of Medical Oncology University Medical Center Utrecht the Netherlands 4e Nascholing Targeted Therapy April
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationTrials in Elderly Melanoma Patients (with a focus on immunotherapy)
Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP
More informationNCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationCombination Immunotherapies: Melanoma
Combination Immunotherapies: Melanoma Igor Puzanov, MD, MSCI, FACP Associate Professor of Medicine, Associate Director of Phase I Drug Development, Director, Melanoma Research, Clinical Director, Renal
More informationNEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
More informationNorthern Ireland Cancer Trials Centre/ Northern Ireland Cancer Trials Network Trials Open to Recruitment March 2014
Northern Ireland Cancer Trials Centre/ Northern Ireland Cancer Trials Network Trials Open to Recruitment March 2014 Bladder HABIO Haematuria Biomarker Study Bowel Cancer NSCCG National Study Of Colorectal
More informationCancerTREATMENT NGS+ NSCLC Summary Report Page 1 of 7 PATIENT SPECIMEN PHYSICIAN
Page 1 of 7 POSITIVE TEST RESULTS Biomarker Result DETECTED NEGATIVE TEST RESULTS FDA Approved Therapies Targeting Molecular Pathway TEST DESCRIPTION: CancerTREATMENT NGS+ uses Next Generation Sequencing
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationPublic-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics
EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC
More informationLocoregional & advanced esophagus or esophagogastric junction cancer
Eloxatin (oxaliplatin) Prior Authorization Request (For Maryland Only) Send completed form to: Case Review Unit CVS/caremark Specialty Programs Fax: 866-249-6155 CVS/caremark administers the prescription
More informationCheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early
April 21, 2015 CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated
More informationBrigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA
Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationWhat s new in prostate cancer research? Highlights of GU-ASCO 2014
review What s new in prostate cancer research? Highlights of GU-ASCO 2014 Cite as: Can Urol Assoc J 2014;8(3-4Suppl2):S8-12. http://dx.doi.org/10.5489/cuaj.2013 Published online April 14, 2014. Abstract
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationNew strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
More informationSommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of
More informationACTIVE CANCER CLINICAL TRIALS November 2015
ACTIVE CANCER CLINICAL TRIALS November 2015 Clinical Trials Nurses Joanie 330-489-1274 Jane 330-588-4589 Tara 330-588-4588 MOLECULAR ANALYSIS FOR THERAPY CHOICE - MATCH Solid tumor or lymphoma that has
More informationPRIMARY TREATMENT CLINICAL PRESENTATION INITIAL EVALUATION. Conclude procedure with/without lymph node dissection
INITIAL EVALUATION History and Physical CXR Pathology review 1 Labs Consider CA125, and pre-operative imaging of abdomen and pelvis Screen for Lynch Syndrome by family history or molecular testing CLINICAL
More informationMedication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010
Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015
More informationNew Advances in Cancer Treatments. March 2015
New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within
More informationOvarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
More informationPARP Inhibitors in Lung Cancer. Primo N. Lara, Jr., MD Professor of Medicine UC Davis Comprehensive Cancer Center
PARP Inhibitors in Lung Cancer Primo N. Lara, Jr., MD Professor of Medicine UC Davis Comprehensive Cancer Center Poly (ADP-ribose) Polymerase (PARP): Mechanism of Action PARPs: family of enzymes that repair
More informationCancer patients waiting for potentially live-saving treatments in UK
Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.
More informationMoving forward, where are we with Clinical Trials?
Moving forward, where are we with Clinical Trials? Dennis A. Wigle Division of Thoracic Surgery Mayo Clinic AATS/STS General Thoracic Surgery Symposium Sunday, April 27 th 2014 2012 MFMER slide-1 Where
More informationGastric or gastroesophageal junction cancer, advanced, as first-line therapy in combination with fluoropyrimidine-based
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Cetuximab INDICATION: chemotherapy Gastric or gastroesophageal junction cancer, advanced, as first-line therapy in combination with fluoropyrimidine-based COMPENDIA
More informationAdiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
More informationChing-Yao Yang, Yu-Wen Tien
Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at
More informationREPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM
REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)
More informationAttached from the following page is the press release made by BMS for your information.
July 22, 2015 CheckMate -025 (global clinical trial), a Pivotal Phase III Opdivo (nivolumab) Renal Cancer Trial Stopped Early (PRINCETON, NJ, July 20, 2015) Bristol-Myers Squibb Company (NYSE:BMY) announced
More informationMechanism Of Action of Palbociclib & PFS Benefit
A Phase II Randomized Controlled Trial of Palbociclib & Tamoxifen/Fulvestrant in Postmenopausal Women and Men With Hormone-Receptor Positive, HER2- Negative Metastatic Breast Cancer (MBC) Protocol Chair:
More informationOne out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3
1. What is cancer? 2. What causes cancer?. What causes cancer? 3. Can cancer be prevented? The Facts One out of every two men and one out of every three women will have some type of cancer at some point
More informationChemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group
Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationGuidelines for Management of Renal Cancer
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
More informationLocalised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment
Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The
More informationFoundational Issues Related to Immunotherapy and Melanoma
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationRecognizing Value in Oncology Innovation. Thomas F. Goss, PharmD, Emilie H. Picard, MS, and Andrew Tarab, MHA
White Paper JUNE 2012 Recognizing Value in Oncology Innovation Thomas F. Goss, PharmD, Emilie H. Picard, MS, and Andrew Tarab, MHA Boston Healthcare Associates, Inc., Boston, MA, and Washington, DC Recognizing
More informationWHITE PAPER SEPT 2015
WHITE PAPER SEPT 2015 LIQUID BIOPSY FOR THE DETECTION AND MONITORING OF CANCER: ANALYSIS OF 96 HOTSPOT MUTATIONS VIA PLASMA DERIVED CIRCULATING TUMOR DNA PATHWAY GENOMICS CANCER AND SOMATIC MUTATIONS The
More informationNational Cancer Drugs Fund List Ver5.1
National Cancer Drugs Fund List Ver5.1 NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and Information Nursing Trans. & Corp. Ops. Commissioning Strategy Finance
More informationProtein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
More informationNational Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.
Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under
More informationOsteosarcoma: treatment beyond surgery
Osteosarcoma: treatment beyond surgery Eric Chow, DVM DACVS Sue Downing, DVM DACVIM-Oncology Providing the best quality care and service for the patient, the client, and the referring veterinarian. Osteosarcoma
More informationGuidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationBREAST. An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With Her2 Positive (Her2+) Metastatic Breast Cancer
BREAST Triple negative ABI-007-MBC-001 TnAcity NCT01881230 A phase 2/3, multi-center, open-label, randomize3d study of weekly nab-paclitaxel in combination with gemcitabine or carboplatin, compared to
More informationUpdates in Prostate Cancer Therapy Sequencing Strategies. Debates and Didactics in Hematology and Oncology. July 26, 2015.
Updates in Prostate Cancer Therapy Sequencing Strategies Debates and Didactics in Hematology and Oncology July 26, 2015. Sea Island, GA Bradley C. Carthon, MD. Ph.D. Assistant Professor, Winship Cancer
More informationLung Cancer. Advances in Lung Cancer Treatment
Lung Cancer Advances in Lung Cancer Treatment Treatment for lung cancer is changing rapidly. There are new therapies that target specific molecular changes that drive the growth and spread of the lung
More informationGenomic Clinical Trials: NCI Initiatives
Genomic Clinical Trials: NCI Initiatives James H. Doroshow, M.D. Deputy Director for Clinical and Translational Research National Cancer Institute National Cancer Advisory Board Washington, DC December
More informationCancer is the leading cause of death for Canadians aged 35 to 64 and is also the leading cause of critical illness claims in Canada.
Underwriting cancer In this issue of the Decision, we provide an overview of Canadian cancer statistics and the information we use to make an underwriting decision. The next few issues will deal with specific
More information